A total of 32 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of Canada, in the last twelve months resulting in a total deal value of over $486.6 million. In the LTM period, July 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $264.9 million, resulting in an average deal value of $44.2 million during that month. On the other hand, the month of June 2021 was the most prolific in terms of deal volume, recording a total of 7 deals, resulting in an average deal value of $1.5 million during that month.
Of the 32 deals, the deal secured between Alexandria Venture Investments; Amplitude Ventures Inc; Canada Pension Plan Investment Board; Fidelity Management & Research Company; Khosla Ventures LLC; Magnetic Ventures LLC; SoftBank Vision Fund 2; True Ventures and Deep Genomics Inc, was the largest Private Equity/Venture Financing deal in the Canada Pharmaceuticals sector, which was valued at $180.0 million and was completed on July 28, 2021. The second-largest deal was between China Life Health Fund; CITIC Construction Investment Co., Ltd.; Guangfa Qianhe Investment Co Ltd; Leading Capital; Pan Lin Capital; Shenzhen Venture Capital Investment Co Ltd and Virogin Biotech Ltd, while the third-largest deal was between Brace Pharma Capital LLC; CaaS Capital Management; Eventide Asset Management, LLC; F-Prime Inc; JM Family Enterprises, Inc.; Northleaf Capital Partners Ltd; Orbimed Advisors LLC; PFM Health Sciences LP; Point72, L.P.; Ridgeback Capital Investment LLC; Sectoral Asset Management Inc; Sixty Degree Capital Inc; Surveyor Capital Ltd; Takeda Ventures Inc; Teralys Capital Inc; Versant Venture Management LLC and Turnstone Biologics Inc. The China Life Health Fund; CITIC Construction Investment Co., Ltd.; Guangfa Qianhe Investment Co Ltd; Leading Capital; Pan Lin Capital; Shenzhen Venture Capital Investment Co Ltd-Virogin Biotech Ltd deal and the Brace Pharma Capital LLC; CaaS Capital Management; Eventide Asset Management, LLC; F-Prime Inc; JM Family Enterprises, Inc.; Northleaf Capital Partners Ltd; Orbimed Advisors LLC; PFM Health Sciences LP; Point72, L.P.; Ridgeback Capital Investment LLC; Sectoral Asset Management Inc; Sixty Degree Capital Inc; Surveyor Capital Ltd; Takeda Ventures Inc; Teralys Capital Inc; Versant Venture Management LLC-Turnstone Biologics Inc deal were valued at $120.0 million and $80.0 million, respectively. The fourth-largest deal was between Amplitude Ventures Inc; Driehaus Capital Management LLC; Fonds de solidarite FTQ; Investissement Quebec Inc; Lumira Capital Investment Management Inc; Orbimed Advisors LLC-Congruence Therapeutics Inc valued at $50.0 million, whereas the deal between Air Street Capital LLP; Amplitude Ventures Inc; Fifty Years Fund; Jonathan Milner; Phoenix Venture Partners LP-Valence Discovery valued at $8.5 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $438.5 million and accounted for nearly 90.11% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward